K
Kaoru Tsuchiya
Researcher at University of Yamanashi
Publications - 151
Citations - 3697
Kaoru Tsuchiya is an academic researcher from University of Yamanashi. The author has contributed to research in topics: Hepatocellular carcinoma & Internal medicine. The author has an hindex of 28, co-authored 120 publications receiving 3003 citations.
Papers
More filters
Journal ArticleDOI
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
Masatoshi Kudo,Osamu Matsui,Namiki Izumi,Hiroko Iijima,Masumi Kadoya,Yasuharu Imai,Takuji Okusaka,Shiro Miyayama,Kaoru Tsuchiya,Kazuomi Ueshima,Atsushi Hiraoka,Masafumi Ikeda,Sadahisa Ogasawara,Tatsuya Yamashita,Tetsuya Minami,Koichiro Yamakado +15 more
TL;DR: The Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma proposed by the Japan Society of Hepatology was updated in June 2014 at a consensus meeting of the Liver Cancer Study Group of Japan.
Journal ArticleDOI
Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection
Yasuhiro Asahina,Kaoru Tsuchiya,Nobuharu Tamaki,Itsuko Hirayama,Tomohiro Tanaka,Mitsuaki Sato,Yutaka Yasui,Takanori Hosokawa,Ken Ueda,Teiji Kuzuya,Hiroyuki Nakanishi,Jun Itakura,Yuka Takahashi,Masayuki Kurosaki,Nobuyuki Enomoto,Namiki Izumi +15 more
TL;DR: Age was the strongest risk factor for a nonvirological response to interferon‐based antiviral therapy and patients at a higher risk for HCC are identified at an earlier age and treatment is initiated.
Journal ArticleDOI
α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C
Yasuhiro Asahina,Kaoru Tsuchiya,Takashi Nishimura,Masaru Muraoka,Yuichiro Suzuki,Nobuharu Tamaki,Yutaka Yasui,Takanori Hosokawa,Ken Ueda,Hiroyuki Nakanishi,Jun Itakura,Yuka Takahashi,Masayuki Kurosaki,Nobuyuki Enomoto,Mina Nakagawa,Sei Kakinuma,Mamoru Watanabe,Namiki Izumi +17 more
TL;DR: Post‐IFN treatment ALT and AFP levels are significantly associated with hepatocarcinogenesis and suppression of these values after IFN therapy reduces HCC risk even in patients without HCV eradication.
Journal ArticleDOI
Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update
Masatoshi Kudo,Osamu Matsui,Namiki Izumi,Masumi Kadoya,Takuji Okusaka,Shiro Miyayama,Koichiro Yamakado,Kaoru Tsuchiya,Kazuomi Ueshima,Atsushi Hiraoka,Masafumi Ikeda,Sadahisa Ogasawara,Tatsuya Yamashita,Tetsuya Minami +13 more
TL;DR: The revision of these TACE failure definitions was approved by over 85% of HCC experts and descriptions similar to those in the previous version were approved.
Journal ArticleDOI
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma†
Tokuzo Arao,Kazuomi Ueshima,Kazuko Matsumoto,Tomoyuki Nagai,Hideharu Kimura,Satoru Hagiwara,Toshiharu Sakurai,Seiji Haji,Akishige Kanazawa,Hisashi Hidaka,Yukihiro Iso,Keiichi Kubota,Mitsuo Shimada,Tohru Utsunomiya,Masashi Hirooka,Yoichi Hiasa,Yoshikazu Toyoki,Kenichi Hakamada,Kohichiroh Yasui,Takashi Kumada,Hidenori Toyoda,Shuichi Sato,Hiroyuki Hisai,Teiji Kuzuya,Kaoru Tsuchiya,Namiki Izumi,Shigeki Arii,Kazuto Nishio,Masatoshi Kudo +28 more
TL;DR: Although the sample size was relatively small, FGF3/FGF4 amplification, a poorly differentiated histological type, and multiple lung metastases were frequently observed in responders to sorafenib, and treatment with a low dose of sorAFenib was partially effective for stably and exogenously expressed FGF4 tumors, while being less effective in tumors expressing EGFP or FGF2.